Skip to main content
Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc. — Investor Relations & Filings

Ticker · MNMD ISIN · CA60255C8850 LEI · 549300QY8KN1O6RPFJ13 US Manufacturing
Open in API
Filings indexed 439 across all filing types
Latest filing 2024-10-17 Capital/Financing Update
Country CA Canada
Listing US MNMD

About Mind Medicine (MindMed) Inc.

https://ir.mindmed.co/

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company's research and development pipeline focuses on innovative treatments derived from psychedelics and other novel compounds. These candidates, which include substances with and without acute perceptual effects, are designed to target key neurotransmitter pathways. MindMed's mission is to deliver therapies that address unmet patient needs in psychiatry, with clinical programs investigating treatments for conditions such as Major Depressive Disorder.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a securities purchase agreement, issuance of shares, exchange of shares for warrants, and amendments to registration rights agreements. It details financing activities including private placements and warrant issuances. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. The focus on securities issuance and exchange agreements aligns with capital raising and financing updates. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing transactions, supporting a high confidence score.
2024-10-17 English
424B7
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(7) related to a shelf registration statement on Form S-3. It details the offer and resale of common shares by selling stockholders, including information about the securities, plan of distribution, risk factors, and legal matters. The document is a registration and offering prospectus supplement, not a financial report, earnings release, or management discussion. It is a capital markets document related to financing activities, specifically the resale of shares by selling stockholders. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information rather than a brief announcement or a report publication notice.
2024-10-17 English
Regulatory Filings 2024
Regulatory Filings
2024-09-26 English
4
Director's Dealing
2024-09-26 English
4
Director's Dealing
2024-09-26 English
Regulatory Filings 2024
Regulatory Filings
2024-09-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.